No abstract

We report on a multifunctional nucleic acid, termed AptamiR, composed of an aptamer domain and an antimiR domain. This composition mediates cell specific delivery of antimiR molecules for silencing of endogenous micro RNA. The introduced multifunctional molecule preserves cell targeting, anti-proliferative and antimiR function in one 37-nucleotide nucleic acid molecule. It inhibits cancer cell growth and induces gene expression that is pathologically damped by an oncomir. These findings will have a strong impact on future developments regarding aptamer- and antimiR-related applications for tumor targeting and treatment.

We have synthesized a light-activatable ("caged") derivative of glucosamine-6-phosphate (GlcN6P), which only upon irradiation becomes a cofactor for the glmS riboswitch. This glmS riboswitch maintains its activity when embedded in the 3'-untranslated region of eukaryotic mRNA molecules and caged GlcN6P reduces the amount of translated EGFP upon irradiation with light in vitro.

Functional nucleic acids, such as aptamers and allosteric ribozymes, can sense their ligands specifically, thereby undergoing structural alterations that can be converted into a detectable signal. The direct coupling of molecular recognition to signal generation enables the production of versatile reporters that can be applied as molecular probes for various purposes, including high-throughput screening. Here we describe an unprecedented type of a nucleic acid-based sensor system and show that it is amenable to high-throughput screening (HTS) applications. The approach detects the displacement of an aptamer from its bound protein partner by means of luminescent oxygen channeling. In a proof-of-principle study we demonstrate that the format is feasible for efficient identification of small drug-like molecules that bind to a protein target, in this case to the Sec7 domain of cytohesin. We extended the approach to a new cytohesin-specific single chain DNA aptamer, C10.41, which exhibits a similar binding behavior to cytohesins but has the advantage of being more stable and easier to synthesize and to modify than the RNA-aptamer M69. The results obtained with both aptamers indicate the general suitability of the aptamer-displacement assay based on luminescent oxygen channelling (ADLOC) for HTS. We also analyzed the potential for false positive hits and identified from a library of 18,000 drug-like small molecules two compounds as strong singlet-oxygen quenchers. With full automation and the use of commercially available plate readers, we estimate that the ADLOC-based assay described here could be used to screen at least 100,000 compounds per day.

This chapter describes cell-type specific aptamers and their use in diagnostics and therapy. Aptamers are single-stranded oligo(deoxy)nucleotides that selectively bind to their target molecules with high affinity. Cell-type specific aptamers in particular can be identified via SELEX using isolated surface proteins or whole cells as targets.Cell-type specific aptamers have been mostly selected targeting cancer cells, which essentially take into account that about 20 % of the deaths worldwide are due to cancer and cancer-related diseases. In the early stages of cancer, circulating cancer cells are very rare. Cancer cell-targeting aptamers allow the identification of these rare circulating cells, thereby providing new tools for early cancer detection and diagnosis. Furthermore, they can be easily synthesized with a variety of modifications. In this regard tumor cell-targeting aptamers are employed as potential delivery vehicles, whereas they are equipped with various cargo molecules, such as toxins, chemotherapeutics, or siRNA molecules, that allow for the development of cell-specific treatment regimens and the decrease of unwanted side effects. Contents